CS Paper Radar

Beyond Random Splits: Evaluating Drug-Target Affinity Models Under Chemically and Biologically Motivated Distribution Shifts Copy

Minjae Chung, Clara Li, Malar Paavai Muthukumaran, Shaunna Wang, Aniket Ramkrishnan Iyer, Shaun Qien Yeau Tan, Harinishree Sathu, Micky C. Nnamdi, J. Ben Tamo, Benoit Louis Marteau, May Dongmei Wang

cs.LG ·submitted 2026-10-02 15:33 UTC · v1
published

Abstract

Drug-target affinity (DTA) prediction is widely used to prioritize candidate compounds before costly experimental screening. DTA models are often compared under a single data split, even though deployment may require extrapolation to new chemical series, new protein targets, or both. We ask whether the distribution shift used for evaluation changes which architecture appears best. We curate 718,800 unique drug-protein pairs from the ChEMBL and BindingDB datasets. We compare a Morgan-fingerprint + protein-CNN baseline with 12 controlled architectures that combine four drug representations with three ESM-2 interaction modes. Mean validation RMSE increases from 0.950 and 0.945 under scaffold and fingerprint-cluster OOD to 1.299 and 1.321 under protein-cluster and dual OOD. Model rankings are similar across the two chemical shifts (tau = 0.79), but agreement with scaffold OOD falls under protein OOD (tau = 0.39) and reverses under dual OOD (tau = -0.55). Held-out evaluation, repeated seeds, group-aware bootstrap analysis, and a size-matched control support the same conclusion: architecture selection depends on the form of extrapolation, not only on average error or training-set size. DTA benchmarks should therefore match the chemical and target shifts expected at deployment.

Comment
Accepted to the NeurIPS 2026 Workshop on AI for Drug Discovery (AI4DD)

Closest papers

Nearest neighbours by meaning across the whole index.

Chemical and geometric representation fidelity improves drug--target affinity prediction

cs.AI q-bio.BMcs.LGstat.ML ·2026-09-02 ·Yixiao Li, Yining Qian, Yefan Chen, Zenghui Chen, Jiayue Sun +3 more
benchmark similarity 0.72
Abstract · 21 pages, 10 figures

Predicting drug--target binding affinity (DTA) requires models to distinguish subtle chemical and structural determinants underlying molecular recognition. Although recent approaches increasingly incorporate richer drug and protein information, such information may be compressed, homogenized or discretized during representation construction, causing affinity-relevant distinctions to be lost before interaction modelling. We hypothesized that this representation-stage information loss constitutes an upstream bottleneck that cannot be reliably overcome by increasingly complex interaction predictors. To test this hypothesis, we developed ReGeoDTA, a representation-preserving framework that maintains affinity-relevant chemical heterogeneity in molecular representations and continuous geometric relationships in protein structures. Across three benchmark datasets, ReGeoDTA consistently improved affinity prediction, and the proposed representation-preserving strategies retained their benefits across diverse DTA architectures. Controlled representation degradation progressively reduced predictive performance, whereas increasing downstream predictor complexity failed to recover information lost during representation construction. These findings identify representation fidelity as an upstream design principle for accurate and generalizable drug--target affinity prediction, with potential implications for computational compound prioritization.

0.23

DPTM-DT: Dual-Pretrained Transformer Multitask Representation Learning for Drug-Target Prediction

cs.LG cs.AI ·2026-08-28 ·Ge Kong
code/data similarity 0.72
Abstract

Drug-target relation prediction supports candidate screening, drug repositioning, and mechanism analysis. Existing models often use incomplete drug or protein representations, model cross-modal interactions shallowly, or train affinity regression and interaction classification separately, although these tasks describe closely related views of the same drug-target pair. This paper presents DPTM-DT, a dual-pretrained Transformer framework for multitask drug-target prediction. DPTM-DT combines GROVER molecular graph embeddings, ESM protein language-model embeddings, and CTD physicochemical descriptors, then exchanges drug-target information through bidirectional cross-modal attention. A shared pair representation is used for continuous affinity regression, high-affinity binary classification, and six-level affinity classification. Experiments on Davis and KIBA cover random 80/20 and DeepDTA-style standard splits. On the random 80/20 split, DPTM-DT achieves MSE/CI values of 0.193/0.917 on Davis and 0.120/0.918 on KIBA. It also reports binary AUPR/MCC values of 0.727/0.654 and 0.798/0.689, and six-class Macro-F1/Top-2 values of 0.800/0.932 and 0.815/0.962 on Davis and KIBA, respectively. Across the reported regression, binary classification, and multiclass classification settings, DPTM-DT achieves the best overall performance among the compared methods. Results under the standard split show the same relative trend. Ablations indicate that dual target representation, gated fusion, and cross-modal attention each contribute to the final performance. Code and supplementary materials are available at: anonymous.4open.science/r/DPCM-DT-74E0.

0.26

PETA:Parameter-Efficient Test-Time Adaptation for Virtual Screening

cs.LG ·2026-08-20 ·Jia-Qi Lin, Yinghua Yao, Chang-Dong Wang, Yew-Soon Ong, Yuangang Pan
similarity 0.71
Abstract

Accurately ranking active ligands for a target protein pocket from massive chemical libraries remains a central challenge in virtual screening. DrugCLIP and its recent extensions substantially accelerate this process by encoding protein pockets and molecules into a shared embedding space. Despite this progress, further performance improvements typically require retraining the entire model, incurring substantial computational overhead and making target-specific customization inefficient. In this work, we formulate the specialization of pretrained virtual screening models to individual pockets as a test-time adaptation problem and propose PETA, a parameter-efficient framework that directly adapts pretrained model at test time. Given a target pocket, PETA constructs pocket-specific negatives through molecular diffusion and chemical validity filtering, and further moves them toward the reference ligand retrieved from structural databases via embedding-space mixup to create more challenging ranking tasks. A ranking objective then places greater emphasis on suppressing high-scoring invalid candidates that could contaminate the top-ranked screening results, providing structured supervision for lightweight adaptation. Experiments across diverse benchmarks demonstrate that this lightweight, pocket-specific adaptation outperforms both pretrained and fully retrained baselines while updating only the LayerNorm parameters, which account for approximately $0.03\%$ of the full model.

0.16

HierDTA: Hierarchical Structure-Aware Representation Learning for Drug--Target Affinity Prediction

cs.LG cs.AI ·2026-10-19 ·Huangchao Xu, Baohua Zhang, Qian Liu, Zhong Jin, Yi Du
published similarity 0.69
Abstract · 20 pages, 7 figures

Drug--target affinity (DTA) prediction plays an important role in computer-aided drug discovery, where reliable computational models can help prioritize compound--protein pairs before experimental validation. A key challenge in DTA prediction is to effectively mine multi-level molecular information from drug structures while accurately modeling the binding-site environment of target proteins. To address these issues, we introduce HierDTA, a hierarchical structure-aware framework for DTA prediction. \textcolor{black}{HierDTA represents each drug as an atom--motif heterogeneous graph and introduces an augmentation module that propagates functional-motif semantics to the corresponding atoms. For proteins, kinase-domain structures are converted into residue interaction graphs. The resulting atom and residue representations are integrated using cross-attention to capture pair-specific relationships, while molecule fingerprints and pretrained ESM-2 embeddings provide complementary global information. Compared with state-of-the-art methods, HierDTA achieves superior performance on the Davis dataset across all metrics and attains the highest \(r_m^2\) of 0.791 on KIBA. It also exhibits strong generalization under cold-start settings, particularly on KIBA, where MSE is reduced by 21.7\% in the unseen-protein scenario. Ablation study and interpretability analysis supported the contributions of the hierarchical augmentation and interaction components.} Case studies further showed that HierDTA provided early enrichment of candidate bioactive compounds. These results indicate that HierDTA is an effective framework for affinity prediction and target-specific virtual screening.

0.31

Recent Advances in Deep Learning-Based Drug-Target Binding Affinity Prediction

cs.LG ·2026-08-13 ·Jafin Khan, Md Hossain Shuvo
benchmark similarity 0.69
Abstract

Computational approaches to drug discovery involve multiple sub-problems, and among them, drug-target binding affinity prediction plays an important role. Despite recent advances, accurately predicting binding affinity remains an open research area. The major objective of our paper is to perform a comprehensive review and comparative analysis of recent machine learning methods for drug-target binding affinity prediction, with a focus on identifying strengths, limitations, and research gaps. We review representative recent deep learning approaches that use common benchmark datasets and evaluation metrics, covering a range of neural network architectures and representation strategies. In addition, we analyze seven widely used benchmark datasets and commonly adopted evaluation metrics for drug-target binding affinity prediction. Our analysis indicates that although many methods report strong performance on standard benchmarks, their effectiveness is often influenced by dataset bias and limited evaluation settings. Furthermore, most methods exhibit reduced performance in cold-start scenarios, highlighting challenges in generalization. We identify several limitations of current approaches, including dataset imbalance, the lack of standardized evaluation, limited real-world applicability, and challenges in cold-start scenarios. We also discuss future research directions, including better dataset design, more robust evaluation methods, improved handling of cold-start problems, and the integration of multimodal representations.

0.04

STORM: A Lightweight Structure-Free Model for Binding Affinity Prediction

cs.LG q-bio.QM ·2026-11-18 ·Ayush Pandit, Rohan V. Koodli, Wei Deng, Roxana Daneshjou, Ron O. Dror
similarity 0.68
Abstract · 9 pages, 3 figures

Accurately predicting a small molecule's binding affinity to a protein, a critical task in drug discovery, remains challenging. Physics-based approaches like free-energy perturbation (FEP) have very high computational costs and require expert setup. Recent machine learning--based cofolding models have reported accuracy approaching that of FEP---and at least one of them, Boltz-2, has already been widely adopted for affinity prediction---but they remain expensive for large computational screens and even more expensive for retraining on newly collected experimental data. To address these challenges, we introduce STORM: Similarity Transfer from Observed Reference Molecules. STORM is a fast, simple machine learning model that ensembles many small model fusions of diverse protein and molecule representations for binding affinity prediction. Trained on the same data, STORM matches or exceeds the accuracy of Boltz-2 on multiple evaluation datasets, while delivering a speed improvement of over five orders of magnitude for both inference and training. Our results also suggest opportunities to substantially improve affinity prediction accuracy by integrating historical experimental affinity data with structural and biophysical information.

0.22

Molecular Prior Networks

cs.LG cs.AIcs.CE ·2026-11-03 ·Pawel Gomoluch, Anthony Bradley
publishedbenchmark similarity 0.67
Abstract · Accepted to the NeurIPS 2026 Workshop on AI for Drug Discovery: Bridging the Translation Gap

Predicting affinity between small molecules and their protein targets remains one of the central problems in drug discovery. Due to the substantial cost of wet-lab experiments, machine learning models of drug-target affinity are usually trained on relatively small datasets, ranging from tens to hundreds of molecules. Given the inherent difficulty of generalization between different targets and chemical series, existing datasets of protein-ligand affinities are typically not used for new projects. At the same time, tabular foundation models, including Prior-data Fitted Networks, have recently shown how transformers can be used to solve machine learning problems in a single forward pass of the network, after being trained over a large corpus of, typically, synthetic datasets. Inspired by that line of work, we propose a novel affinity modelling approach, in which the labels of the query molecules are predicted from the labelled support molecules in a single forward pass of a transformer model. The model is trained on thousands of existing affinity datasets, enabling it to capture the general patterns of molecular activity across different targets, chemical series and dataset sizes. For the smallest support sets, our model matches the state of the art on the regression variant of the FS-Mol benchmark, while being faster than existing methods, thanks to the lack of task-specific training. A comparison against a reduced variant of our architecture, which amounts to kernel regression in a meta-learned feature space, shows that the predictive performance of the transformer model is only partially explained by simple molecular similarity.

0.25

Benchmarking Peptide-Protein Affinity Prediction Across Peptide and Target Shifts

cs.LG q-bio.QM ·2026-08-31 ·Jiaxin Tian, Darren An, Jun Li
similarity 0.67
Abstract · 11 pages, 6 figures, 2 tables

Peptide-protein affinity models are often evaluated with a single data split, obscuring whether they interpolate among measurements for observed targets or generalize across peptide or target shifts. We integrated three sources of quantitative peptide-protein binding data to obtain 11,349 deduplicated pairs and benchmarked ten peptide representations, ESM-2 protein embeddings, and six regressors under peptide-similarity, within-target, and leave-target-out partitions. Across 60 matched representation-regressor configurations, mean test Spearman correlations were 0.462, 0.669, and 0.530, respectively. The top configuration shifted from ECFP-16 count fingerprints with random forest in the first two settings to HELM-BERT with Extra Trees when exact target sequences were excluded. Representation-rank correlations ranged from -0.042 to 0.624 across partitions, whereas regressor-rank correlations ranged from 0.771 to 0.943. Learning curves showed that representation differences were largest with limited supervision and narrowed as training data increased. PeptideCLM-2 adaptation and simple element-wise interaction features provided no consistent gain over a frozen encoder and direct concatenation under the tested protocols. These conclusions are specific to a dataset that pools transformed Kd, Ki, and IC50 measurements and to target exclusion at the exact-sequence level. Peptide-protein affinity benchmarks should therefore align data partitions with the intended use and jointly assess the effects of data scale, molecular representation, and downstream learner.

0.31